SYDNEY, Australia — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the filing of a provisional patent application supporting a novel therapeutic strategy designed to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer...

WALTHAM, Mass. — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IND application to initiate a Phase 1 clinical trial for...

CAMBRIDGE, Mass. — Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced that the first participant has been dosed in BEACON, a pivotal Phase 3 clinical trial evaluating rugonersen, an investigational ASO for the treatment of Angelman syndrome. “The dosing of the first participant in the BEACON (NCT07605429)...